01 Rising Incidence of Cancer A rise in demand for the detection of cell and tissue characteristics and the prevalence of cell-based diseases like cancer are anticipated to expedite the market over the forecast period. Cancer is among the leading reasons of death worldwide. As per the National Cancer Institute, the number of new cancer cases is expected to increase to 23.6 million by 2030; as per WHO, cancer accounted for approximately 8.8 million deaths in 2015. Similarly, according to Cancer Facts and Figures, 2020, published by the American Cancer Society, cancer is the second most common cause of death in the U.S., with an expected 1.8 million new cancer cases and 606,520 related deaths in 2020. Africa, Asia, and Central and South America account for nearly 60% of cancer deaths worldwide, and more than 60% of new cancer cases are diagnosed annually in similar regions.
02 Increasing Awareness Programs for Cancer Screening The global histology and cytology market is bolstered by the growing demand for histology and cytology products due to surging screening awareness. The growth in awareness programs undertaken by organizations such as National Cervical Cancer Coalition, WHO, CDC, and the U.S. Preventive Services Task Force (USPSTF), for cancer screening, is a crucial factor expected to boost the market in the coming years. In addition, major market players are also undertaking initiatives to increase awareness about cervical and vaginal cancer screening, helping avoid deaths.Additionally, National Breast and Cervical Cancer Early Detection Program (NBCCEDP) is a program initiated by the CDC. It provides access to timely cervical and breast cancer screening and diagnostic assistance to uninsured, underserved, and low-income women. Tennessee Breast & Cervical Screening Program is an initiative of the Tennessee government that aims to reduce breast cancer disparities. Such initiatives are expected to drive the market soon.
01 Low Sensitivity of Cytology Tests Cytology plays an important role in the detection of cancer. However, it is observed that cytology and histological testing sensitivity is low for early-stage cancer. A risk of an unreliable cytopathologic diagnosis of low-grade neoplasms has been observed, which is attributed to the poor manifestation of cellular and nuclear signs of neoplasm malignancy. Many different markers were developed to improve the sensitivity during the diagnosis of cancer samples. According to the study published by the National Institutes of Health, sensitivity for low-grade and high-grade bladder cancer was 38.0% and 52.0%, respectively. Hence, the low sensitivity of the cytological tests is likely to restrain the histology and cytology market growth.
01 Technological Developments Histological techniques have largely been considered the primary means of determining tissue organization. However, these methods are also vital diagnostic tools for assessing chronic diseases due to several developments over the past three decades. Rapid advancements in microscopy and immunohistochemistry will likely drive these developments and the market. For instance, in July 2020, researchers from the University of Chicago's Medicine Comprehensive Cancer Center worked with European researchers to create a deep-learning algorithm that could deduce molecular alterations from histology images for several tumor types. It also provided a distinction between normal tissue and spatially resolved tumors. Such potential of implementing AI in the analysis of histology images is expected to assist clinicians in developing personalized treatment plans for patients.Additionally, liquid-based cytology a recent advancement offers better clarity, requires less screening time, facilitates uniform smearing, and results in improved handling of inflammatory and hemorrhagic samples. Increasing demand for advanced diagnostic procedures to screen cancer is a pivotal aspect expected to create opportunities for the cytology and histology testing market over the forecast period.
April 2026 Leica Biosystems expanded its digital pathology portfolio by launching AI-powered histology workflow solutions integrating automated tissue staining, slide preparation, and digital image analysis.
February 2026 Roche Diagnostics introduced enhanced tissue diagnostics solutions with advanced immunohistochemistry (IHC) and digital pathology capabilities supporting precision oncology.
October 2025 Agilent Technologies expanded its pathology portfolio with new automated staining systems and digital pathology software for histology and cytology laboratories.
June 2025 Sakura Finetek launched upgraded histology laboratory automation systems featuring improved tissue processing, embedding, and slide preparation technologies.